宁晓红;王毓洲;孙昭;李霁;周艳萍;白春梅;
NING Xiao-hong1,WANG Yu-zhou1,SUN Zhao1,LI Ji2,ZHOU Yan-ping1,BAI Chun-mei11Department of Oncology,2Department of Pathology,Peking Union Medical College Hospital,ChineseAcademy of Medical Sciences & Peking Union Medical College,Beijing 100730,China

• 1:中国医学科学院北京协和医学院北京协和医院肿瘤内科
• 2:中国医学科学院北京协和医学院北京协和医院病理科

摘要(Abstract)：

目的探讨肺癌组织ERCC1(excision repair cross-complementation group1)表达水平对晚期非小细胞肺癌含铂化疗疗效及生存期的预测价值。方法采用免疫组织化学方法对39例非小细胞肺癌患者的石蜡包埋肿瘤标本进行ERCC1检测,分析其与化疗反应率及生存期间的关系。结果 56.4%(22/39)的肿瘤组织呈ERCC1高表达。ERCC1表达与患者性别、年龄、病理类型、肿瘤分化程度、吸烟史及吸烟指数均无相关性;ERCC1低表达患者对含铂一线化疗的反应率优于ERCC1高表达者,P<0.05。但ERCC1表达水平对患者总生存(overall survival,OS)和疾病进展(time to progression,TTP)时间没有明显影响。结论 ERCC1在肺癌组织的表达水平可能成为预测晚期非小细胞肺癌患者一线含铂化疗方案疗效的因素之一。
Objective To explore the role of expression of excision repair cross-complementation group 1 (ERCC1) in predicting the outcomes of platinum-based chemotherapy in patients with end-stage non-small-cell lung cancer. Methods The expression of ERCC1 was detected with immunohistochemical methods in paraffin-embeded tumor specimens obtained from 39 patients with chemo-naive non-small-cell lung cancer. The relationship between ERCC1 expression and the response rate of platinum-based chemotherapy as well as its possible values in predicting overall survival (OS) and time to progression (TTP) were analyzed. Results ERCC1 was highly expressed in 39 tumors (56.4%). The expression of ERCC1 showed no association with gender,age,pathologic type,grade of differentiation,smoking history,and smoking index. The response rate of platinum-based chemotherapy was significantly higher in patients with low ERCC1 expression (P<0.05). Furthermore,ERCC1 expression had no notable influence on OS and TTP. Conclusion The expression of ERCC1 in lung tumor may be useful in predicting the effectiveness of platinum-based chemotherapy for end-stage non-small-cell lung cancer.

关键词(KeyWords)： ERCC1;非小细胞肺癌;化疗;免疫组织化学
excision repair cross-complementation group 1; non-small cell lung cancer; chemotherapy; immunohistoche-mistry

Abstract:

Keywords:

基金项目(Foundation):

作者(Author): 宁晓红;王毓洲;孙昭;李霁;周艳萍;白春梅;
NING Xiao-hong1,WANG Yu-zhou1,SUN Zhao1,LI Ji2,ZHOU Yan-ping1,BAI Chun-mei11Department of Oncology,2Department of Pathology,Peking Union Medical College Hospital,ChineseAcademy of Medical Sciences & Peking Union Medical College,Beijing 100730,China

Email:

DOI:

参考文献(References)：

• [1]Schiller JH,Harrington D,Belani CP,et al.Eastern Coop-erative Oncology Group.Comparison of four chemotherapy regimens for advanced non small cell lung cancer[J].N Engl J Med,2002,346:92-98.
• [2]Soria JC.ERCC1-tailored chemotherapy in lung cancer:the first prospective randomized trial[J].J Clin Oncol,2007,25:2648-2649.
• [3]Hwang IG,Ahn MJ,Park BB,et al.ERCC1expression as a prognostic marker in N2(+)nonsmall-cell lung cancerpatients treated with platinum-based neoadjuvant concurrent chemoradiotherapy[J].Cancer,2008,113:1379-1386.
• [4]Azuma K,Sasada T,Kawahara A,et al.Expression of ERCC1and class III beta-tubulin in non-small cell lung canc-er patients treated with carboplatin and paclitaxel[J].Lung Cancer,2009,64:326-333.
• [5]Chen S,Zhang J,Wang R,etal.The platinum-based treat-ments for advanced non-small cell lung cancer,is low/nega-tive ERCC1expression better than high/positive ERCC1ex-pression?A meta-analysis[J].Lung Cancer,2010-06-9[Epub ahead of print].http://www.cancer.gov/cancer-topics/types/lung.
• [6]Reynolds C,Obasaju C,Schell MJ,et al.Randomized phase III trial of gemcitabine-based chemotherapy with in si-tu RRM1and ERCC1protein levels for response prediction in non-small-cell lung cancer[J].J Clin Oncol,2009,27:5808-5815.
• [7]Vilmar AC,Santoni-Rugiu E,Sφrensen JB.ERCC1and histopathology in advanced NSCLC patients randomized in a large multicenter phase III trial[J].Ann Oncol,2010,21:1817-1824.
• [8]Planchard D,DomontJ,Taranchon E,etal.The NER pro-teins are differentially expressed in ever smokers and in nev-er smokers with lung adenocarcinoma[J].Ann Oncol,2009,20:1257-1263.
• [9]Shimizu J,Horio Y,Osada H,et al.mRNA expression of RRM1,ERCC1and ERCC2is not associated with chemo-sensitivity to cisplatin,carboplatin and gemcitabine in hu-man lung cancer cell lines[J].Respirology,2008,13:510-517.
• [10]Booton R,Ward T,Ashcroft L,et al.ERCC1mRNA ex-pression is not associated with response and survival after platinum-based chemotherapy regimens in advanced non-small cell lung cancer.J Thorac Oncol,2007,2:902-906.
• [11]Lee KH,Min HS,Han SW,et al.ERCC1expression by immunohistochemistry and EGFR mutations in resected non-small cell lung cancer[J].Lung Cancer,2008,60:401-407.
• [12]Su C,Zhou S,Zhang L,et al.ERCC1,RRM1and BRCA1mRNA expression levels and clinical outcome of ad-vanced non-small cell lung cancer[J].Med Oncol,2010-05-14[Epub ahead of print].http://www.springer.com/medicine/oncology/journal/12032.
• [13]Yin J,Vogel U,Guo L,et al.Lack of association between DNA repair gene ERCC1polymorphism and risk of lung cancer in a Chinese population[J].CancerGenetCytogen-et,2006,164:66-70.
• [14]Yin Z,Su M,Li X,et al.ERCC2,ERCC1polymorphisms and haplotypes,cooking oil fume and lung adenocarcinoma risk in Chinese non-smoking females[J].J Exp Clin Canc-er Res,2009,28:153.